Based on the Basilea Pharmaceutica AG stock forecast from 0 analysts, the average analyst target price for Basilea Pharmaceutica AG is not available over the next 12 months. Basilea Pharmaceutica AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Basilea Pharmaceutica AG is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Basilea Pharmaceutica AG’s stock price was CHF 45.65. Basilea Pharmaceutica AG’s stock price has changed by +0.88% over the past week, +2.70% over the past month and +0.11% over the last year.
No recent analyst target price found for Basilea Pharmaceutica AG
No recent average analyst rating found for Basilea Pharmaceutica AG
Company Overview Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 167b, Allschwil, Switzerland, 4123 Read Less
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatmen...Read More
Frequently Asked Questions About Basilea Pharmaceutica AG (BSLN:SW) Stock
Stock Target Advisor's fundamental analysis for Basilea Pharmaceutica AG's stock is Slightly Bullish .
Unfortunately we do not have enough data on BSLN:SW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BSLN:SW's stock to indicate what its average analyst target is.
BSLN:SW stock's Price/Earning ratio is 53.60.
Our analysis grades BSLN:SW stock's Price / Earning ratio at F. This means that BSLN:SW stock's Price/Earning ratio is above 71% of the stocks in the Biotechnology sector in the SW exchange.
Based on this BSLN:SW may be a overvalued for its sector.
The last closing price of BSLN:SW's stock was CHF 45.65.
The most recent market capitalization for BSLN:SW is CHF 0.55B.
Unfortunately we do not have enough analyst data on BSLN:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Basilea Pharmaceutica AG's stock.
As per our most recent records Basilea Pharmaceutica AG has 156 Employees.
Basilea Pharmaceutica AG's registered address is Grenzacherstrasse 487, Basel, Switzerland, 4058.
You can get more information about it from Basilea Pharmaceutica AG's website at https://www.basilea.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Basilea Pharmaceutica AG (BSLN:SW) Stock
Stock Target Advisor's fundamental analysis for Basilea Pharmaceutica AG's stock is Slightly Bullish .
Unfortunately we do not have enough data on BSLN:SW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BSLN:SW's stock to indicate what its average analyst target is.
BSLN:SW stock's Price/Earning ratio is 53.60.
Our analysis grades BSLN:SW stock's Price / Earning ratio at F. This means that BSLN:SW stock's Price/Earning ratio is above 71% of the stocks in the Biotechnology sector in the SW exchange.
Based on this BSLN:SW may be a overvalued for its sector.
The last closing price of BSLN:SW's stock was CHF 45.65.
The most recent market capitalization for BSLN:SW is CHF 0.55B.
Unfortunately we do not have enough analyst data on BSLN:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Basilea Pharmaceutica AG's stock.
As per our most recent records Basilea Pharmaceutica AG has 156 Employees.
Basilea Pharmaceutica AG's registered address is Grenzacherstrasse 487, Basel, Switzerland, 4058.
You can get more information about it from Basilea Pharmaceutica AG's website at https://www.basilea.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BSLN:SW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
